At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed advanced endometrial carcinoma with any histology, including clear cell and serous papillary carcinoma
- ✓Surgical stage III disease: positive adnexa, tumor invading serosa, positive pelvic/paraaortic nodes, bowel mucosa involvement, intra-abdominal metastases, positive pelvic washings, or vaginal involvement within radiation port
- ✓Prior surgery with hysterectomy and bilateral salpingo-oophorectomy, maximally debulked to residual disease ≤2 cm
- ✓No recurrent disease, no parenchymal liver metastases, no disease outside the abdomen
- ✕Recurrent disease
- ✕Parenchymal liver metastases
- ✕Disease outside the abdomen
- ✕Other prior or concurrent malignancy within past 5 years except adequately treated nonmelanoma skin cancer
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma
In Brief
A Phase 3 clinical trial evaluating Doxorubicin Hydrochloride, Cisplatin, and 3 other interventions for Endometrial Adenocarcinoma and 5 related conditions. Completed, enrolled 659 participants across 1 site.
Detailed Summary
Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens plus radiation therapy in treating patients who have stage III or stage IV endometrial cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen plus radiation therapy is more effective for endometrial cancer.
Study Details
Timeline
Interventions
Given IV
Given IV
Given SC
Given SC
Given IV